Primum non nocere: Utility and outcomes of pediatric breast ultrasound.

To assess the use and outcomes of ultrasound for the evaluation of breast signs and symptoms in pediatric females. A retrospective database review identified all patients ≤18-years-old who underwent breast ultrasound at an academic institution over a 20-year period. Each symptomatic site was designated a case and analyses were performed on each case. Imaging findings were obtained from the radiology reports. Clinical and pathology data were obtained from the medical records. Descriptive statistics were performed. The final cohort comprised 124 cases in 101 patients. Mean age was 15 years (range 1–18). The most common indication for ultrasound was a palpable lump (71%). Thirty-seven cases (30%) demonstrated no sonographic correlate to the symptom; 36 (29%) had a benign correlate. The most common benign correlates were abscess/phlegmon and cyst. All cases of abscess/phlegmon had infectious symptoms. Fifty-one cases (41%) demonstrated a sonographic mass that was not characteristically benign. Of these indeterminate masses, 27 were recommended for biopsy, 13 for short-interval follow-up, and 6 had no recommendation. Of 27 biopsied masses, 63% were fibroadenomas. No symptoms were due to malignancy. Therefore, the NPV of ultrasound was 100% and the PPV 0%. In this cohort of pediatric and adolescent patients, malignancy was never the cause of breast symptoms. Imaging yielded false positives with a biopsy recommendation in 22% of cases. Ultrasound provided value in evaluating infectious symptoms. Given the extreme rarity of breast cancer in this population, surveillance may be a safe alternative for most indeterminate lesions. • While there are well-established guidelines for imaging breast symptoms in adults but the literature in pediatric patients is sparse. • Malignancy was never the cause of breast symptoms in our cohort of 124 ultrasound cases over 20 years. • Imaging led to false positives with biopsy recommendation in 22% of cases. • Close imaging or clinical surveillance may be a safe alternative to biopsy, although larger studies are needed. • Current BI-RADS guidelines may not be applicable to the pediatric patient population. [ABSTRACT FROM AUTHOR]